Research programme: immune checkpoint protein inhibitors - Aurigene

Drug Profile

Research programme: immune checkpoint protein inhibitors - Aurigene

Alternative Names: AUNP-12; AUR-012; NP-12 - Aurigene; PD-1 peptide antagonist - Aurigene; PDCD-1 protein inhibitors - Aurigene

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aurigene Discovery Technologies
  • Class Peptides
  • Mechanism of Action CD274 antigen inhibitors; PDCD 1 protein inhibitors; Programmed cell death 1 ligand 2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bacterial infections; Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in India (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in India (SC)
  • 13 Feb 2014 Aurigene and Pierre Fabre enter into a collaborative licensing, development and commercialisation agreement for AUNP 12 in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top